Skip to main content
RCKT
NASDAQ Life Sciences

FDA授予Rocket Pharma的Kresladi加速批准，这是一种基因性免疫缺陷治疗方法

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
9
Price
$5.08
Mkt Cap
$509.189M
52W Low
$2.19
52W High
$8.26
Market data snapshot near publication time

summarizeSummary

Rocket Pharmaceuticals获得了FDA对其基因治疗产品Kresladi的加速批准，用于治疗儿童严重白细胞粘附缺陷-I（LAD-I）。这是一项极其重要的积极发展，尤其考虑到该公司最近在其10-K中概述的挑战，包括工作人员减少和另一个项目的临床停摆。该批准提供了一个关键的产生收入的产品，并验证了Rocket的基因治疗平台用于罕见疾病。此外，该公司获得了一个罕见儿童疾病优先审查凭证，计划将其货币化以增强财务灵活性。这一里程碑标志着Rocket的一个重要转折点，转向商业化和潜在增长。投资者现在将密切关注Kresladi的商业推出和货币化优先审查凭证的策略。

在该公告发布时，RCKT的交易价格为$5.08，交易所为NASDAQ，所属行业为Life Sciences，市值约为$5.1亿。 52周交易区间为$2.19至$8.26。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed RCKT - Latest Insights

RCKT
Apr 28, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
9
Rocket Pharmaceuticals Secures $180M Non-Dilutive Capital from PRV Sale, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
RCKT
Apr 27, 2026, 9:42 AM EDT
Filing Type: SC TO-I
Importance Score:
7
Rocket Pharmaceuticals Launches Option Exchange Program to Re-incentivize Employees with Underwater Stock Options
Sentiment: Neutral
View Wiseek Article
RCKT
Apr 06, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Rocket Pharmaceuticals Seeks Shareholder Approval for Stock Option Exchange Program to Boost Employee Retention
Sentiment: Neutral
View Wiseek Article
RCKT
Mar 27, 2026, 12:10 PM EDT
Source: Reuters
Importance Score:
8
Rocket Pharma Shares Plunge 15% as Commercialization Doubts Overshadow FDA Approval
Sentiment: Negative
View Wiseek Article
RCKT
Mar 27, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
9
Rocket Pharmaceuticals Secures FDA Accelerated Approval for KRESLADI™ Gene Therapy and Rare Pediatric Disease PRV
Sentiment: Positive
View Wiseek Article
RCKT
Mar 27, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
FDA Grants Accelerated Approval for Rocket Pharma's Kresladi, a Genetic Immunodeficiency Treatment
Sentiment: Positive
View Wiseek Article
RCKT
Mar 24, 2026, 8:16 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Rocket Pharmaceuticals Seeks Shareholder Approval for Stock Option Exchange Program to Boost Employee Retention
Sentiment: Neutral
View Wiseek Article
RCKT
Mar 10, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
8
Rocket Pharmaceuticals Establishes $100M At-The-Market Offering Program, Replaces Prior Agreement
Sentiment: Negative
View Wiseek Article
RCKT
Mar 10, 2026, 5:19 PM EDT
Filing Type: 424B5
Importance Score:
8
Rocket Pharmaceuticals Launches $100M At-The-Market Offering to Boost Capital Runway
Sentiment: Negative
View Wiseek Article
RCKT
Mar 02, 2026, 4:17 PM EST
Filing Type: S-3
Importance Score:
8
Rocket Pharmaceuticals Files $400M Universal Shelf Registration Amidst Operational Challenges
Sentiment: Negative
View Wiseek Article